ALCMI Forms Clinical Research Collaboration With Response Genetics

The Addario Lung Cancer Medical Institute (ALCMI) has signed a letter of intent (LOI) collaboration agreement with Response Genetics (RGI), on molecular diagnostic testing and banking of advanced-stage lung cancer tissues.

Steven Young, president and COO of ALCMI, said: ALCMI’s CASTLE Network will be the only resource of its kind in Lung Cancer that facilitates the collection of biospecimens from advanced-stage patients.

Under the terms of the agreement, a tissue bank will be housed at Response Genetics’ Los Angeles laboratory facility.

Bonnie Addario, founder of ALCMI and the Bonnie J Addario Lung Cancer Foundation, said: We are thrilled to collaborate with Response Genetics, and as a Lung Cancer survivor I know first-hand just how critical these tests will be to bringing the right therapies to each patient in a time-sensitive manner.

David Carbone, chair of Scientific Leadership Board at ALCMI, said: Coupled with the routine determination of a panel of documented, clinically-significant biomarkers by Response Genetics, the ALCMI CASTLE Network will help lead the way as the Lung Cancer research community’s premier, open access source for high quality proteomics, genomics, target validation, and correlative science analyses.